[Response of growth hormone to sandostatin and bromocriptine and prognostic value of prolactin levels in serum and thyroliberin test in patients with active acromegaly].
Usefulness of determination of blood serum prolactin concentration and the result of thyroliberin (TRH) stimulation test for predicting the magnitude of growth hormone (GH) response to the administration of sandostatin and bromocriptine has been evaluated in 14 patients with active acromegaly. No relation was found between the occurrence of hyperprolactinemia and the response of GH to the administration of sandostatin and bromocriptine. Analysis of GH secretion after TRH administration made possible the selection of a group of acromegalic patients with paradoxical increase in GH secretion in response to TRH in whom the administration of sandostatin caused a significant decrease in blood serum concentration of GH following the administration of sandostatin. TRH stimulation test had, however, no value in predicting the effect of bromocriptine on GH secretion.
Gasińska
T
T
I Klinika Chorób Wewnetrznych Slaskiej AM, Katowicach.
Nowak
S
S
D000172:Acromegaly / Q000188:drug therapy* / Q000378:metabolism; D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D005260:Female; D013006:Growth Hormone / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D011379:Prognosis; D011388:Prolactin / Q000097:blood*; D013973:Thyrotropin-Releasing Hormone
D001971:Bromocriptine; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D013006:Growth Hormone; D015282:Octreotide
Odpowiedź hormonu wzrostu na sandostatyne i bromokryptyne a wartość prognostyczna stezenia prolaktyny w surowicy i testu z tyreoliberyna u chorych z aktywna akromegalia.